Innovative start-up helps doctors, scientists and industry balance coagulation risks

For many doctors caring for seriously ill patients, for example, in stroke units and cancer wards, maintaining the life-saving balance between bleeding and thro...

“You discover one thing – and then 10 new questions arise”

COVID-19, diabetes, heart disease, and the impact of dog ownership on humans are just some of multitasker Tove Fall’s areas of research. However, her current fo...

“We need to build flexible operating theatres”

Flexible operating theatres, micro-sensors on surgeons to monitor their well-being and 3D images projected onto organs to be operated on. These are a few ideas ...

Column: Repurposing as a golden ticket to approval

"Hopefully, in the end, patients will be winners by receiving on-label treatments for which benefit-risk has been properly assessed." In a column Marie Gårdmark...

Lucy Robertshaw: Artificial intelligence – is this really going to transform a patient’s life?

In a column Lucy Robertshaw reflects on how AI and new regulations will affect healthcare, innovation and the lives of future patients.

He got inside the head of Sweden’s vaccine hunter

The hunt for the COVID-19 vaccine is the theme of the new book Vaccinjägaren (The Vaccine Hunter). It tells the story of Richard Bergström’s mission as Sweden’s...

When carelessness, forgetfulness and coincidence become the researcher’s best friend

Forgetfulness, coincidence and a stroke of luck hardly make up a fruitful method of serious research. Or do they? Actually, a number of important medical advanc...

"Are we doing business the wrong way around in the Life Science Sector?"

For the past 50 years we have created solutions for problems that we thought would solve the problems. Pharmaceuticals have created big block buster drugs which...

Han bygger ett konstgjort hjärta

I över 20 år har Azad Najar arbetat med sin modell för ett konstgjort hjärta som nu utvecklas i ett företag i Västerås.

Noxious parasite forms hybrids and deceives the immune system

The small parasite Trypanosoma cruzi has a nasty ability to cause serious illness. Researchers at the Karolinska Institutet have now mapped its ability to decei...

Covid-19-studie med Farxiga nådde inte målen

Astra Zenecas läkemedel Farxiga har inte nått målen för behandling av covid-19 i en fas III-studie.

Real Heart tappar vd

Christina Hugosson avgår från rollen som vd på medtechbolaget.

Fokus Patient blir internationellt

I oktober arrangerar Fokus Patient konferenser i dagarna tre. Fokus ligger i år på internationella samarbeten.

Lucy Robertshaw: Did you know Stockholm wants to be in top 5 in the world for Life Sciences?

Karolinska Institutet Solna Campus has certainly become the next “Kendall Square”, writes Lucy Robertshaw in a column.

Ny projektledare på Real Heart

Fredrik Pahlm från ABB Robotics leder utvecklingen av bolagets hjärtpump.

Claims of life science companies fleeing abroad is a myth according to survey

The claim that life science companies are moving abroad is exaggerated. In fact, only a tiny percentage is leaving the country, according to a survey.

ALS – When the body has given up, but the brain persists

The nerve disease ALS gradually deprives the patient of control over the muscles and, eventually, also of speech. The eyes continue to function, though, and wit...

Ny chef på Real Heart

Christina Hugosson leder in medtechbolaget i en ny fas.

Årets mest lästa krönikor och opinionsartiklar

Branschspaningar och reflektioner är och har alltid varit en viktig del av Life Science Swedens redaktionella innehåll. När 2021 nu snart är till ända har vi sa...

Giulia Gaudenzi: Innovation for good

"I challenge the innovator landscape to take a mental leap. Relying on innovation-solely to end inequality is not enough, therefore consciously and purposively ...

Pilots want to live too

Kalmar tar täten inom e-hälsa

Under det senaste decenniet har digitalisering och e-hälsolösningar skapat nya möjligheter för medicintekniska företag. I Kalmar län har regionen skapat en e-hä...

Nytt avtal för Alligator

Alligator bioscience har tecknat ett licensavtal med ett privatägt kinesiskt företag som nu får rättigheter till en av lundabolagets antikroppar.

Beslut om open access dåligt för forskarna

I ett debattinlägg skriver två forskare att den europeiska plan för open access som planeras träda ikraft 2020 innebär stora problem.